Japanese conductor Ozawa to undergo cancer treatment

Japanese conductor Ozawa to undergo cancer treatment

TOKYO, Japan - Prominent Japanese conductor Seiji Ozawa reacts during a press conference at a hotel in Tokyo on Jan. 7, 2010. Ozawa said he was diagnosed with early stage of esophageal cancer and will cancel all of his 30 concert engagements through June.

  • Product Code
  • ILEA001140116
  • Registered date
  • 2010/1/07 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2010 Kyodo News
  • Media size
  • 1280 × 1889 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 464.63(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Research to start on blood tests to detect 13 cancer types

    Research to start on blood tests to detect 13 cancer types

    TOKYO, Japan - Researchers announce the commencement of a project to develop ways of detecting 13 types of cancer from a single blood sample at a press conference in Tokyo on Aug. 18, 2014. Making the announcement were Kenji Kurata (L), president of the New Energy and Industrial Technology Development Organization, Tomomitsu Hotta (C), president of the National Cancer Center, and Tetsu Yonehara, head of Toray Industries Inc.'s New Frontiers Research Laboratories.
      Novartis management replaced

      Novartis management replaced

      TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.
        Novartis management replaced

        Novartis management replaced

        TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
          Novartis management replaced

          Novartis management replaced

          TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
            Ghostwriter for well-known Japanese composer

            Ghostwriter for well-known Japanese composer

            TOKYO, Japan - Takashi Niigaki, a music lecturer, speaks at a press conference at a Tokyo hotel on Feb. 6, 2014, the day after confessing that he has worked as a ghostwriter for Mamoru Samuragochi, a well-known Japanese composer, for nearly 20 years. At the press conference, Niigaki cast doubt over the composer's claim that he cannot hear.
              Amari to miss key TPP talks due to cancer treatment

              Amari to miss key TPP talks due to cancer treatment

              TOKYO, Japan - Akira Amari, Japan's minister in charge of the Trans-Pacific Partnership free trade talks, announces at a press conference at the Cabinet Office in Tokyo on Dec. 5, 2013, that he will not be able to attend a TPP ministerial negotiating session starting Dec. 7 in Singapore, as he has been diagnosed with tongue cancer. Tokyo will send Amari's deputy, Yasutoshi Nishimura, senior vice minister of the Cabinet Office, instead to the four-day meeting.
                Novartis scandal

                Novartis scandal

                TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                  Novartis scandal

                  Novartis scandal

                  TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                    Novartis Pharma

                    Novartis Pharma

                    TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.
                      Tokyo International Conference on African Development

                      Tokyo International Conference on African Development

                      YOKOHAMA, Japan - Participants of the fifth Tokyo International Conference on African Development line up for group photos at a hotel in Yokohama, near Tokyo, on June 1, 2013.